Intel stock extends gains after report of possible U.S. government stake
Investing.com - Baird maintained its Outperform rating and $18.00 price target on Voyager Therapeutics (NASDAQ:VYGR) stock following an in-person meeting with company management. According to InvestingPro data, the stock is currently trading significantly below analysts’ consensus target range of $9-30, despite maintaining a Fair overall financial health rating.
The research firm highlighted the breadth of Voyager’s internal pipeline and advancing gene therapy partnerships, particularly noting the recent expansion of the company’s Alzheimer’s pipeline.
Baird emphasized that Voyager’s Alzheimer’s programs provide investors with exposure to a diverse range of therapeutic approaches in this disease area.
The firm expressed encouragement about potential data from Voyager’s Neurocrine-partnered gene therapy program, which is scheduled to enter clinical trials in early 2026.
Baird noted that initial data from this partnership could potentially derisk Voyager’s TRACER capsid technology next year, representing a key inflection point for the company.
In other recent news, Voyager Therapeutics has announced a new gene therapy program targeting the APOE gene, expanding its Alzheimer’s disease portfolio. This program employs Voyager’s TRACER capsid technology to address the high-risk APOE4 variant while boosting the protective APOE2 variant. Preclinical studies have shown promising results, with significant reductions in APOE4 and increased APOE2 expression in test mice. Voyager’s Alzheimer’s portfolio now includes four assets, including an anti-tau antibody and a tau silencing gene therapy. Additionally, Voyager reported a scientific advancement in drug delivery to the brain, with a new AAV capsid named VCAP-102 showing improved gene transfer efficiency. This discovery, published in Molecular Therapy, highlights the potential for more effective treatments for neurological diseases. The company is advancing towards Investigational New Drug filings for two gene therapy programs this year. These developments underscore Voyager’s strategic focus on multi-modality approaches to meet neurological disease treatment needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.